These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38896996)

  • 1. Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
    Chew SM; Ferraro E; Safonov A; Chen Y; Kelly D; Razavi P; Robson M; Seidman AD
    Eur J Cancer; 2024 Aug; 207():114175. PubMed ID: 38896996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities in receipt of 1-
    Pilehvari A; Kimmick G; You W; Bonilla G; Anderson R
    Breast Cancer Res; 2024 Oct; 26(1):144. PubMed ID: 39425174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
    Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S
    Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients.
    Kubeczko M; Gabryś D; Krzywon A; Jarząb M
    Br J Radiol; 2024 Oct; 97(1162):1627-1635. PubMed ID: 39120877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
    Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
    Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U
    Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
    Kimmick G; Pilehvari A; You W; Bonilla G; Anderson R
    Breast Cancer Res Treat; 2024 Nov; 208(2):263-273. PubMed ID: 38922546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
    Bardia A; Cortés J; Bidard FC; Neven P; Garcia-Sáenz J; Aftimos P; O'Shaughnessy J; Lu J; Tonini G; Scartoni S; Paoli A; Binaschi M; Wasserman T; Kaklamani V
    Clin Cancer Res; 2024 Oct; 30(19):4299-4309. PubMed ID: 39087959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
    Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
    Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
    Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Önder T; Ateş Ö; Öner İ; Karaçin C
    Clin Breast Cancer; 2024 Aug; 24(6):519-526. PubMed ID: 38879437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer.
    Lobo-Martins S; Corredeira P; Cavaco A; Rodrigues C; Piairo P; Lopes C; Fraga J; Silva M; Alves P; Wachholz Szeneszi L; Barradas A; Castro Duran C; Antunes M; Nogueira-Costa G; Sousa R; Pinto C; Ribeiro L; Abreu C; Torres S; Quintela A; Mata G; Megías D; Ribot J; Serre K; Casimiro S; Silva-Santos B; Diéguez L; Costa L
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
    BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population.
    Chen BF; Tsai YF; Chao TC; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Lai JI; Tseng LM; Huang CC
    Clin Exp Med; 2024 Aug; 24(1):185. PubMed ID: 39133334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
    Guliyev M; Şen GA; Gültürk İ; Majidova N; Akdağ G; Ahadzade A; Turna H; Demirci NS
    Breast Cancer Res Treat; 2024 Jun; 205(3):633-640. PubMed ID: 38526689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
    Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
    Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
    Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
    Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.